(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/256586 A3

(51) International Patent Classification:
A61K 31/4353 (2006.01) *A61K 31/33* (2006.01)
A61K 31/437 (2006.01) *A61K 31/00* (2006.01)

(21) International Application Number:
PCT/US2022/032042

(22) International Filing Date:
03 June 2022 (03.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/196,339	03 June 2021 (03.06.2021)	US
63/290,019	15 December 2021 (15.12.2021)	US
63/346,120	26 May 2022 (26.05.2022)	US

(71) Applicant: **CHINOOK THERAPEUTICS, INC.** [US/US]; 1600 Fairview Avenue East, Suite 100, Seattle, Washington 98102 (US).

(72) Inventors: **SHENG, Tao**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **DING, Jinyue**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **GOMEZ, Robert**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **POWELL, David Andrew**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **ROSE, Victoria Elizabeth**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **MATEYKO, Nicholas Anton**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **BESTVATER, Brian P.**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA). **OIKE, Taro**; 887 Great Northern Way #210, Vancouver, British Columbia V5T 4T5 (CA).

(74) Agent: **BATES, Caleb A.** et al.; P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
12 January 2023 (12.01.2023)

WO 2022/256586 A3

(54) Title: SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention or amelioration of a disease, condition or disorder through inhibition of the complement alternative pathway.